Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ: CRSP )

47.91 -2.52 (-5.00%)
Official Closing Price Updated: 4:15 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,675,127
Open 51.23
Bid (Size) 47.50 (2)
Ask (Size) 48.00 (1)
Prev. Close 50.43
Today's Range 47.34 - 51.47
52wk Range 36.52 - 90.62
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Market Whales and Their Recent Bets on CRSP Options
Via Benzinga
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga

Performance

YTD
+15.64%
+15.64%
1 Month
+8.32%
+8.32%
3 Month
-4.94%
-4.94%
6 Month
-2.56%
-2.56%
1 Year
-42.96%
-42.96%

More News

Read More
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Via Benzinga
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
The Ultimate Healthcare Stock to Buy With $500 Right Now
Via The Motley Fool
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
Via The Motley Fool
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
Via Investor's Business Daily
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Via The Motley Fool
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Via The Motley Fool
Exposures Product Safety
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox
Via Benzinga
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
Via MarketBeat
Exposures Product Safety
My Top 5 Stocks to Buy in Early 2025
Via The Motley Fool
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
Via Benzinga
3 Unstoppable Stocks to Buy in 2025
Via The Motley Fool
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Via The Motley Fool
Vertex's Pain Drug: Big Pharma's Next Major Success?
Via MarketBeat
Exposures Product Safety
My 10 Top Stocks to Buy to Start the New Year Off Right
Via The Motley Fool
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
3 Mid-Cap Stocks That Could Take Off in 2025
Via The Motley Fool
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Via MarketBeat
Exposures Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.